{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-015982","form_type":"8-K","ticker":"GKOS","cik":"0001192448","company_name":"GLAUKOS Corp","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.850874+00:00","generated_at":"2026-06-22T12:16:29.273348+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Glaukos Q3 net loss $27.6M ($0.58 EPS); revenue down 4.6% YoY to $71.3M; raises 2022 sales outlook","bullets":["Net sales $71.3M, down 4.6% reported (1.6% constant currency) vs $74.7M in Q3 2021.","Net loss $27.6M ($0.58 diluted) vs net income $6.2M ($0.13) in prior year, which included $30M litigation settlement.","Non-GAAP net loss $21.3M ($0.45) vs non-GAAP net loss $14.7M ($0.31) in Q3 2021.","Updated 2022 net sales guidance to $278-280M from prior $275-280M; cash and investments $371M.","Glaucoma net sales $53.7M, Corneal Health $17.5M; GAAP gross margin 76%, non-GAAP 84%."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-015982","json":"https://secwatch.observer/filing/0001558370-22-015982.json","markdown":"https://secwatch.observer/filing/0001558370-22-015982.md","text":"https://secwatch.observer/filing/0001558370-22-015982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/0001558370-22-015982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/gkos-20221102x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:16:29.273348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a343e14f9ab56c5564913e9004cea96c4ad2d25","claim":"GLAUKOS Corp reported third quarter ended September 30, 2022 results: revenue $71.3 million, net income $27.6 million, EPS ($0.58) per diluted share. Guidance raised.","evidence_excerpt":"of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2022. Key highlights include: ● Net sales of $71.3 million in Q3 2022. ● Glaucoma net sales of $53.7 million and Corneal Health net sales of $17.5 million in Q3 2022. ● Gross margin of approximately 76% and non-GAAP gross margin of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1192448/000155837022015982/0001558370-22-015982-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$71.3 million"},{"label":"Net income","value":"$27.6 million"},{"label":"EPS","value":"($0.58) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}